GCP
EDIT icon

Gill Capital Partners’s Editas Medicine EDIT Stock Holding History

Gill Capital Partners’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.38K Hold
425
– – ﹤0.01% 598
2026
Q1 		$1.05K Buy
+425
New +$899 ﹤0.01% 596

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Gill Capital Partners's EDIT Position: Q2 2026 in Review

Gill Capital Partners held its Editas Medicine (EDIT) position steady in Q2 2026 at 425 shares worth $1.38K. The position accounts for ﹤0.01% of the portfolio, ranked #598.

Gill Capital Partners first reported a position in EDIT in Q1 2026 and has held it in 2 quarters since. 216 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • Gill Capital Partners held 425 shares of Editas Medicine worth $1.38K as of Q2 2026.
  • Gill Capital Partners left its Editas Medicine share count unchanged in Q2 2026.
  • Editas Medicine made up ﹤0.01% of Gill Capital Partners's portfolio in Q2 2026, its #598 holding.
  • Gill Capital Partners first reported a position in Editas Medicine in Q1 2026 and has held it in 2 quarters since.
  • 216 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Gill Capital Partners's 13F filing for Q2 2026, filed 20 Aug 2026.